Efficacy and tolerability of perampanel in patients with seizures in real-world clinical practice: A systematic review and meta-analysis.

ABSTRACT: Objectives: The aim of this study was to systematically review the efficacy and tolerability of perampanel (PER) when used as add-on treatment or monotherapy in patients with epilepsy aged 12 years and older in routine clinical practice. Methods: Electronic and clinical trials databases were searched for observational studies of PER published up to 1 March 2022. The outcomes of interest were responder rates, adverse effects (AEs), and withdrawal rates. Subgroup analyses were performed to explore the potential factors that might affect the efficacy and safety of PER usage. Results: A total of 56 studies, which included 10,688 patients, were enrolled. The results showed that after 3, 6, and 12 months of PER treatment, the pooled 50% responder rates in patients with epile

SUBMITTER: Hou L 

PROVIDER: S-EPMC10086234 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature